A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers

J. Malfetano, J. B. Beecham, B. N. Bundy, K. D. Hatch

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Twenty-four evaluable patients with advanced or recurrent epithelial ovarian carcinoma who progressed on platinum-containing combination chemotherapy were treated with medroxyprogesterone acetate (C.T. Provera) 50 mg orally three times a day until progression of disease. One patient had a partial response (4.2%), 9 patients had stable disease (37.5%), and 14 (58.3%) had increasing disease. The 95% upper confidence limit for response is less than or equal to 18.3%. There was no toxicity associated with its use. C.T. Provera has limited activity in patients with epithelial ovarian cancer who have failed combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)149-151
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number2
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers'. Together they form a unique fingerprint.

  • Cite this